(5-Amino-2-fluorophenyl)(4-methylpiperazin-1-yl)methanone | 1156817-81-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (5-Amino-2-fluorophenyl)(4-methylpiperazin-1-yl)methanone
• 英文别名: (5-amino-2-fluorophenyl)-(4-methylpiperazin-1-yl)methanone
• CAS: 1156817-81-0
• 化学式: C₁₂H₁₆FN₃O
• mdl: MFCD12423217
• 分子量: 237.277
• InChiKey: DAPYBBFCGSXMRN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  49.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (5-Amino-2-fluorophenyl)(4-methylpiperazin-1-yl)methanone 、 4-三氟甲基苯基异氰酸酯 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 1-[4-Fluoro-3-(4-methyl-piperazine-1-carbonyl)-phenyl]-3-(4-trifluoromethyl-phenyl)-urea
  参考文献：
  名称：

  Exploration of secondary and tertiary pharmacophores in unsymmetrical N,N′-diaryl urea inhibitors of soluble epoxide hydrolase

  摘要：

  The impact of various secondary and tertiary pharmacophores on in vitro potency of soluble epoxide hydrolase (sEH) inhibitors based on the unsymmetrical urea scaffold 1 is discussed. N,N'-Diaryl urea inhibitors of soluble epoxide hydrolase exhibit subtle variations in inhibitory potency depending on the secondary pharmacophore but tolerate considerable structural variation in the second linker/tertiary pharmacophore fragment. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.03.074
• 作为产物：
  描述：

  (2-Fluoro-5-nitrophenyl)-(4-methylpiperazin-1-yl)methanone 在 甲酸铵 、 铁粉 作用下， 以 水 、 甲苯 为溶剂， 生成 (5-Amino-2-fluorophenyl)(4-methylpiperazin-1-yl)methanone
  参考文献：
  名称：

  Exploration of secondary and tertiary pharmacophores in unsymmetrical N,N′-diaryl urea inhibitors of soluble epoxide hydrolase

  摘要：

  The impact of various secondary and tertiary pharmacophores on in vitro potency of soluble epoxide hydrolase (sEH) inhibitors based on the unsymmetrical urea scaffold 1 is discussed. N,N'-Diaryl urea inhibitors of soluble epoxide hydrolase exhibit subtle variations in inhibitory potency depending on the secondary pharmacophore but tolerate considerable structural variation in the second linker/tertiary pharmacophore fragment. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.03.074

文献信息

• HETEROCYCLIC COMPOUNDS
  申请人：GAUL Christoph

  公开号：US20090203688A1

  公开（公告）日：2009-08-13

  The invention relates to compounds of formula I and salts thereof wherein the substituents are as defined in the specification, processes for the preparation thereof; to pharmaceuticals containing such compounds, in particular for the use in one or more Protein tyrosine kinase mediated diseases.

  该发明涉及公式I的化合物及其盐，其中取代基如规范中定义，以及其制备方法；含有这种化合物的药物，特别用于在一个或多个蛋白酪氨酸激酶介导的疾病中使用。
• PYRROLO [2, 3-D]PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS
  申请人：Novartis AG

  公开号：EP2247591A1

  公开（公告）日：2010-11-10
• US8420657B2
  申请人：——

  公开号：US8420657B2

  公开（公告）日：2013-04-16
• [EN] PYRROLO [2, 3-D] PYRIDINES AND USE THEREOF AS TYROSINE KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES
  申请人：NOVARTIS AG

  公开号：WO2009098236A1

  公开（公告）日：2009-08-13

  The invention relates to compounds of formula (I) and salts thereof formula (I), wherein the substituens are as defined in the specification, processes for the preparation thereof; to pharmaceuticals containing such compounds, in particular for the use in one or more Protein tyrosine kinase mediated diseases.
• Exploration of secondary and tertiary pharmacophores in unsymmetrical N,N′-diaryl urea inhibitors of soluble epoxide hydrolase
  作者：Sampath-Kumar Anandan、Richard D. Gless

  DOI：10.1016/j.bmcl.2010.03.074

  日期：2010.5

  The impact of various secondary and tertiary pharmacophores on in vitro potency of soluble epoxide hydrolase (sEH) inhibitors based on the unsymmetrical urea scaffold 1 is discussed. N,N'-Diaryl urea inhibitors of soluble epoxide hydrolase exhibit subtle variations in inhibitory potency depending on the secondary pharmacophore but tolerate considerable structural variation in the second linker/tertiary pharmacophore fragment. (C) 2010 Elsevier Ltd. All rights reserved.